Bleeding disorders:

Indications for COAGADEX:

In patients with hereditary Factor X deficiency: on-demand treatment and control of bleeding episodes, perioperative management in mild and moderate Factor X deficiency, and routine prophylaxis to reduce frequency of bleeding episodes.

Limitations of Use:

Not studied in perioperative management in major surgery for patients with severe hereditary Factor X deficiency.

Adults and Children:

See full labeling. Give by IV infusion at a rate of 10mL/min; max 20mL/min. Bleeding (<12yrs): initially 30 IU/kg; (≥12yrs): initially 25 IU/kg. Give at first sign of bleeding; repeat every 24hrs until resolved. Perioperative (<12yrs): Dosage Required (IU) = Body Weight (kg) × Desired Factor X Increase (IU/dL or % of normal) × 0.6; (≥12yrs): Dosage Required (IU) = Body Weight (kg) × Desired Factor X Increase (IU/dL or % of normal) × 0.5. Pre-op: calculate dose to raise plasma FX levels to 70–90 IU/dL; Post-op: repeat dose as needed to maintain plasma FX levels at minimum of 50 IU/dL until patient is no longer at bleeding risk. Routine prophylaxis (<12yrs): initially 40 IU/kg twice weekly; (≥12yrs): initially 25 IU/kg twice weekly. Monitor FX levels; adjust to clinical response and FX trough levels of ≥5 IU/dL (max peak 120 IU/dL). All: max 60 IU/kg daily.

Warnings/Precautions:

Monitor for development of Factor X inhibitors. Immediately discontinue if hypersensitivity reactions occur. Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.

Pharmacologic Class:

Clotting factor.

Interactions:

Caution with concomitant other Factor X-containing plasma products (eg, fresh frozen plasma, prothrombin complex concentrates).

Adverse Reactions:

Infusion site erythema/pain, fatigue, back pain; possible antibody formation.

Generic Availability:

NO

How Supplied:

Single-dose vial—1 (w. diluent, supplies)